Myriad Genetics (NASDAQ:MYGN) has been given an average rating of “Hold” by the fourteen brokerages that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $30.45.
Several research firms recently commented on MYGN. BTIG Research set a $44.00 price target on shares of Myriad Genetics and gave the stock a “buy” rating in a report on Wednesday, February 7th. Leerink Swann raised their price target on shares of Myriad Genetics from $33.00 to $35.00 and gave the stock a “market perform” rating in a report on Wednesday, February 7th. BidaskClub cut shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 28th. ValuEngine cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a report on Tuesday, March 13th. Finally, Morgan Stanley upgraded shares of Myriad Genetics from an “underweight” rating to an “equal weight” rating and set a $28.00 price target for the company in a report on Wednesday, March 21st.
In other news, VP Richard M. Marsh sold 37,654 shares of Myriad Genetics stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $40.25, for a total value of $1,515,573.50. Following the transaction, the vice president now owns 157,648 shares of the company’s stock, valued at $6,345,332. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Gary A. King sold 3,120 shares of Myriad Genetics stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $38.12, for a total transaction of $118,934.40. Following the completion of the transaction, the vice president now directly owns 125,088 shares in the company, valued at approximately $4,768,354.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 54,533 shares of company stock worth $2,133,272. Insiders own 6.70% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Xact Kapitalforvaltning AB bought a new position in shares of Myriad Genetics in the fourth quarter valued at approximately $261,000. MetLife Investment Advisors LLC bought a new position in shares of Myriad Genetics in the fourth quarter valued at approximately $1,022,000. BB&T Securities LLC raised its position in shares of Myriad Genetics by 347.7% in the fourth quarter. BB&T Securities LLC now owns 5,990 shares of the company’s stock valued at $205,000 after purchasing an additional 4,652 shares during the period. Macquarie Group Ltd. raised its position in shares of Myriad Genetics by 7.8% in the fourth quarter. Macquarie Group Ltd. now owns 145,500 shares of the company’s stock valued at $4,998,000 after purchasing an additional 10,500 shares during the period. Finally, Vident Investment Advisory LLC raised its position in shares of Myriad Genetics by 6.5% in the fourth quarter. Vident Investment Advisory LLC now owns 115,121 shares of the company’s stock valued at $3,954,000 after purchasing an additional 7,029 shares during the period.
Shares of MYGN stock traded down $0.51 during trading on Wednesday, hitting $29.04. 501,441 shares of the company were exchanged, compared to its average volume of 724,677. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.81 and a current ratio of 2.05. The stock has a market cap of $2,064.08, a P/E ratio of 27.68, a P/E/G ratio of 2.08 and a beta of 0.52. Myriad Genetics has a twelve month low of $17.50 and a twelve month high of $41.57.
Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.24 by $0.07. The business had revenue of $194.00 million during the quarter, compared to analysts’ expectations of $188.72 million. Myriad Genetics had a net margin of 16.67% and a return on equity of 9.59%. The firm’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period last year, the company posted $0.26 earnings per share. sell-side analysts predict that Myriad Genetics will post 1.15 EPS for the current year.
Myriad Genetics Company Profile
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.